Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focusing on CNS, inflammatory, and cardiometabolic diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024.

Key details include:

• CEO Dr. Laxminarayan Bhat will deliver a corporate update
• A pre-recorded presentation will be available on-demand from September 9, 7:00 a.m. ET
• Management will participate in virtual one-on-one meetings

Investors can access the presentation via a provided webcast link and arrange meetings with management through H.C. Wainwright sales representatives.

CUPERTINO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 26^th Annual Global Investment Conference, taking place September 9-11, 2024.

H.C. Wainwright 26^th Annual Global Investment Conference
Format: Corporate update
Date/Time: Pre-recorded presentation available on-demand Monday, September 9, at 7:00 a.m. ET
Webcast Link: Click Here

Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your H.C. Wainwright sales representative to register for the conference.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

Media Contact:
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783

FAQ

When is Reviva Pharmaceuticals (RVPH) participating in the H.C. Wainwright Global Investment Conference?

Reviva Pharmaceuticals (RVPH) is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.

Who will be presenting for Reviva Pharmaceuticals (RVPH) at the conference?

Dr. Laxminarayan Bhat, the Founder, President, and CEO of Reviva Pharmaceuticals (RVPH), will be presenting at the conference.

What type of presentation will Reviva Pharmaceuticals (RVPH) give at the H.C. Wainwright conference?

Reviva Pharmaceuticals (RVPH) will provide a corporate update through a pre-recorded presentation available on-demand from September 9, 2024, at 7:00 a.m. ET.

Will Reviva Pharmaceuticals (RVPH) management be available for meetings during the conference?

Yes, Reviva Pharmaceuticals (RVPH) management will be participating in virtual one-on-one meetings throughout the event.